Inhibitory effects of podophyllotoxin derivatives on herpes simplex virus replication

Antiviral Chemistry and Chemotherapy

Volumn 9, Issue 3, 1998, Pages 263-267

  Sudo, K ^a,b   Konno, K ^a   Shigeta, S ^b   Yokota, T ^a  

^a Rational Drug Design Laboratories   (Japan)

^b FUKUSHIMA MEDICAL UNIVERSITY   (Japan)

Author keywords

Acyclovir resistant virus; Clinical isolates; G strain; Herpes simplex virus; KOS strain; Podophyllotoxin

Indexed keywords

5' METHOXYPODORHIZOL; DEOXYPODOPHYLLOTOXIN; PODOPHYLLOTOXIN DERIVATIVE; PODORHIZOL; RD 4 6266; RD 4 6276; RD 4 6283; UNCLASSIFIED DRUG;

ANTIVIRAL ACTIVITY; ARTICLE; DRUG POTENCY; HERPES SIMPLEX VIRUS; HUMAN; HUMAN CELL; NONHUMAN; PRIORITY JOURNAL; VIRUS REPLICATION;

EID: 0031746653     PISSN: 09563202     EISSN: None     Source Type: Journal    
DOI: 10.1177/095632029800900307     Document Type: Article

References (26)

1. Beers SA, Imakura Y, Dai HJ, Li DH, Cheng YC & Lee KH (1988) Antitumor agents, 99. Synthetic ring C aromatized podophyllotoxin analogues as potential inhibitors of human and topoisomerase II. Journal of Natural Production 51:901-905.
2. Beutner KR & von Krogh G (1990) Current status of podophyllotoxin for the treatment of genital warts. Seminars in Dermatology 9:148-151.
3. Bonnez M, Elswick RK Jr, Bailey-Farchione A, Hallahan D, Bell R, Isenberg R, Stoler MH & Reichman RC (1994) Efficacy and safety of 0.5% podofilox solution in the treatment and suppression of anogenital warts. American Journal of Medicine 96:420-425.
4. Chatis PA & Crumpacker CS (1992) Resistance of herpesviruses to antiviral drugs. Antimicrobial Agents & Chemotherapy 36:1589-1595.
5. Chen GL, Yang L, Rowe TC, Halligan BD, Tewey KM & Liu LF (1984) Nonintercalative antitumor drugs interfere with the breakage-reunion reaction of mammalian DNA topoisomerase II. Journal of Biological Chemistry 259:13560-13566.
6. Coen DM (1991) The implications of resistance to antiviral agents for herpesvirus drug targets and drug therapy. Antiviral Research 15:287-300.
7. Crumpacker CS, Schnipper LE, Marlowe SI, Kowalsky PN, Hershey BJ & Levin MJ (1982) Resistance to antiviral drugs of herpes simplex virus isolated from a patient treated with acyclovir. New England Journal of Medicine 306:343-346.
8. Ebert SN, Shtrom SS & Muller MT (1990) Topoisomerase II cleavage of herpes simplex virus type 1 DNA in vivo is replication dependent. Journal of Virology 64:4059-4066.
9. Ebert SN, Subramanian D, Shtrom SS, Chung IK, Parris DS & Muller MT (1994) Association between the p170 form of human topoisomerase II and progeny viral DNA in cells infected with herpes simplex virus type I. Journal of Virology 68:1010-1020.
10. Gordaliza M, Castro MA, Garcia Gravalos MD, Ruiz P, Miguel del Corral JM & San Feliciano A (1994) Antineoplastic and antiviral activities of podophyllotoxin related lignans. Archives of Pharmacology 327:175-179.
11. Hammarsten O, Yao X & Elias P (1996) Inhibition of topoisomerase II by ICRF-193 prevents efficient replication of herpes simplex virus type 1. Journal of Virology 70:4523-4529.
12. Hansen HF, Jensen RB, Willumsen AM, Norskov-Lauritsen N, Ebbesen P, Nielsen PE & Buchardt O (1993) New compounds related to podophyllotoxin and congeners: synthesis, structure elucidation and biological testing. Acta Chemica Scandanavica 47:1190-1200.
13. Loike JD & Horowitz SB (1976) Effects of podophyllotoxin and VP-16-213 on microtubule assembly in vitro and nucleoside transport in HeLa cells. Biochemistry 15:5435-5442.
14. Loike JD, Brewer CF, Sternlicht H, Gensler WJ & Horwitz SB (1978) Structure - activity study of the inhibition of microtubule assembly in vitro by podophyllotoxin and its congeners. Cancer Research 38:2688-2693.
15. Manso-Martinez R (1982) Podophyllotoxin poisoning of microtubules at steady-state: effect of substoichometic and superstoichometic concentration of drug. Molecular and Cellular Biochemistry 45:3-11.
16. Maschera B, Ferrazzi E, Rassu M, Toni M & Palu G (1993) Evaluation of topoisomerase inhibitors as potential antiviral agents. Antiviral Chemistry of Chemotherapy 4:85-91.
17. McLaren C, Chen MS, Ghazzouli I, Saral R & Burns WH (1985) Drug resistance patterns of herpes simplex virus isolates from patients treated with acyclovir. Antimicrobial Agents & Chemotherapy 28:740-744.
18. Nishiyama Y, Fujioka H, Tsurumi T, Yamamoto N, Maeno K, Yoshida S & Shimokata K (1987) Effects of the epipodophyllotoxin VP-16-213 on herpes simplex virus type 2 replication. Journal of General Virology 68:913-918.
19. San Feliciano A, Medarde M, Pelaez Lamamie de Clairac R, Lopez JL, Puebla P, Garcia Gravalos MD, Ruiz Lazaro P & Garcia de Quesada MT (1993) Synthesis and biological activity of bromolignans and cyclolignans. Archives of Pharmacology 326:421-426.
20. Savel H (1964) Clinical experiment with intravenous podophyllotoxin. Proceedings of the American Association for Cancer Research 5:56.
21. Stone KM (1995) Human papillomavirus infection and genital warts: update on epidemiology and treatment. Clinical Infectious Diseases 20(Suppl. 1):S91-97.
22. Strauss MJ, Khanna V, Koenig JD, Downs SM, Glodberg SH, Manyak MJ & Patsner B (1996) The cost of treating genital warts. International Journal of Dermatology 35:340-348.
23. Sudo K, Konno K, Yokota T & Shigeta S (1994) A sensitive assay system screening antiviral compounds against herpes simplex virus type 1 and type 2. Journal of Virological Methods 49:169-178.
24. Terada T, Fujimoto K, Nomura M, Yamashita J, Kobunai T, Takeda S, Wieraba K, Yamada Y & Yamaguchi H (1992) Antitumor agents. I. DNA topoisomerase II inhibitory activity and the structural relationship of podophyllotoxin derivatives as antitumor agents. Chemical and Pharmaceutical Bulletin 40:2720-2727.
25. von Krogh G & Maibach HI (1983) Cutaneous cytodestructive potency of lignans. II. A comparative evaluation of macroscopic-toxic influence on rabbit skin subsequent to repeated 10-day applications. Dermatologica 167:70-77.
26. Whitley RJ (1988) Herpes simplex virus infection of central nervous system: a review. American Journal of Medicine 85(Suppl. 2A):61-67.